Navigation Links
Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
Date:12/7/2007

ompany's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
2. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
3. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... BOSTON, Nov. 21 Innerscope Resea... firm specializing in Emotional Response Measureme...utives who will strengthen the,company,s research...,initiatives. , The three appointments, who...de Geoffrey Gill as Chief Financial Officer and Vi...
(Date:11/21/2008)... , COLD SPRING HARBOR, N.Y. (Nov. 21, 2008) Ho...What can the lamprey immune system tell us about e...ations help with efforts to conserve rare species?...duction, and hereditary diseases? Will studies of... , To answer these and other questions in biolog...
(Date:11/21/2008)... WASHINGTON, Nov. 21 New inventio... with a variety of cognitive disabilities lead ful...ience(R) Corporation. Zimman,presented today at t...ington,DC, a meeting organized by The National C...tion to assist people with disabilities. , ...
(Date:11/21/2008)... Winter viruses may be to blame, study suggests ...The season of a baby,s birth may help predict that..., Babies born in autumn -- about four months befo...a 30 percent increased risk of asthma compared to ...study in the first December issue of the American...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3
...s of vitamin C notwithstanding, British researcher...! It is now said that vitamin C reverses pre eclam...e leading contributors to complications in childbi...n lead onto eclampsia which, when left untreated, ...
...hat causes infectious mononucleosis, Epstein-Barr ...o the development of Hodgkin's disease. But no one...BV and Hodgkin's survival, according to researcher... from Northern California Cancer Center in Union C...
...d on more than 1600 women reveals that parathyroid...ne density and cut the risk of fractures in them. ...ium levels in the body. The new aspect of th...ures has opened up the prospect of the hormone bei...
...n from Mayo Foundation in Rochester, Minnesota has...ble metal stents in the digestive tract of people ...ese patients commonly suffer from obstructions and...ke difficulty in swallowing, if the block is in th...
Other Medicine News:
(Date:11/21/2008)... -- Ikaria Holdings, Inc. today announced that it ...New Jersey Technology Council (NJTC), a 1,200-memb...support, networking opportunities, information and...rs. Ikaria earned the award based on criteria incl... provision. , , "We are delighted that the ...
(Date:11/20/2008)...ire/ -- New Jersey American Water has lifted the ...rs in the following municipalities in Middlesex, S...ounty , , , Dunellen , Ediso...South Plainfield , , , , Somerset C...idgewater , Green Brook , Hillsborou...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...re-FirstCall/ -- Duska Therapeutics,Inc., (OTC B...submitted its,pivotal Phase 3 ATPace clinical tri...ssessment (SPA) procedure with the U.S. Food and D...uring an agreement with the FDA, Duska intends to ...cebo-controlled and randomized Phase 3,clinical t...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Mindray to Attend 2007 RSNA Conference in Chicago 6781 1Mindray to Attend 2007 RSNA Conference in Chicago 6781 2Mindray to Attend 2007 RSNA Conference in Chicago 6781 3Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 6779 1Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 6779 2Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 1Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 2Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 3Danaher Closes Subsequent Offering Period for Tektronix 3B Acquires Over 90 25 of TEK Shares 6775 1Danaher Closes Subsequent Offering Period for Tektronix 3B Acquires Over 90 25 of TEK Shares 6775 2
...s TNF-alpha Production Through Inhibition,of PDE-4...ire/ -- Anacor,Pharmaceuticals, a privately held p... from its placebo-controlled Phase 1 trial of,AN27...gation for,the treatment of psoriasis. The trial s...omparable to existing topical,treatments for psori...
...k, June 06, 2007 /PRNewswire-FirstCall/,-- XTL Bio...ompleted the analysis of results from a Phase I cl...c Hepatitis C. This Phase I,trial was a placebo co... evaluated the safety, tolerability and antiviral ... The study enrolled 56,patients into seven cohorts...
Other Medicine Technology:Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 3
Inquire
...are is easy to configure for gravimetric calibrati...ndard method or enter your own parameters (number ... QualiTrace automatically manages the calibration ...from the balance to the software, which establishe...
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile
Reagent Basin, 60mL, 5/Box
Medicine Products: